𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation

✍ Scribed by Martin J Edelman; Frederick J Meyers; Tim R Miller; Stephen G Williams; Regina Gandour-Edwards; Ralph W deVere White

Book ID
117266365
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
130 KB
Volume
55
Category
Article
ISSN
0090-4295

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of carboplatin and paclit
Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma : A Southwest Oncology Group study
✍ Ulka N. Vaishampayan; James R. Faulkner; Eric J. Small; Bruce G. Redman; Wayne L πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 86 KB

## Abstract ## BACKGROUND The purpose of the study was to assess the efficacy and toxicity of carboplatin and paclitaxel administered every 3 weeks in patients with advanced urothelial carcinoma, previously treated with cisplatin‐based therapy. ## METHODS Eligibility included metastatic or local

Platinum-free combination chemotherapy i
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma : A Phase I/II trial of gemcitabine, paclitaxel, and methotrexate
✍ Primo N. Lara Jr; Frederick J. Meyers; Lisa Y. Law; Nancy A. Dawson; Joan Housto πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Platinum‐based regimens have improved response rates and survival in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract. However, the toxicities of platinum‐based chemotherapy are considerable. Regimens with reduced toxicity that are applicab